Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Gestational Diabetes - PrEvention of PostPartum Diabetes Study

NCT05112588 · tracked via the Priya Life Science Sweden tracker
Phase
Not applicable
Started
2021-11-01
Last updated
2024-06-13

Condition(s) studied

Gestational Diabetes

Investigational drug(s) / intervention(s)

Intervention

Intervention: The women randomized to intervention will get support from the Child Health Care unit (CHCU) at every visit with the baby. Before the visit the women will have blood-samples taken and waist and weight measured. The women will also get support from a digital solution, specially developed for this purpose (MyMOWO). The nurse at the CHCU will include information and support to the mother at every visit accort´ding to a special protocol. All women will be carefully examined at baseline, after one and four years will blood-tests, anthropometric measurements and maximal oxygen uptake (VO2max).

Study summary

Gestational diabetes is the most common metabolic abnormality during pregnancy. In a Swedish population 2-10% of all pregnant women are diagnosed with gestational diabetes mellitus (GDM). The frequency differs dependent of methods for screening and diagnostic references, even within Sweden. Women with GDM have about 50% risk to develop manifest type 2 diabetes (T2DM) within 20 years. Most counties in Sweden have a recommendation to follow women with GDM yearly with an examination and an oral glucose tolerance test (OGTT). Unfortunately, this recommendation often fails, partly due to limited resources at the health care units but also due to lack of compliance from the women. Often after the baby is born focus is changed from the mother to the child and only 30.7% of the women with one or more risk factors performed an OGTT, despite stipulated OGTT in local guidelines.

The diagnose GDM is under debate and Sweden has started to implement the recommendations from World Health Organisation (WHO) from 2013 with a lower cut-off for GDM, which will increase diagnostic sensitivity and consequently increase the number of women diagnosed with GDM. The plan was to conduct a randomized, clinical trial testing implementation the new recommendations in Sweden step-wise from 2018 and onwards. The recruitment is now complete and the results are expected to be published in 2021.

The overarching aim of this study is to conduct a randomized, controlled clinical trial to test the effect of a model for a lifestyle intervention in clinical practice, using technical support as well as personal, individual support. The intervention is based on the existing organisation and structure in Primary Care and would thus be inexpensive and straight-forward to implement. An additive aim is to explore background mechanisms for the development of type 2 diabetes in women with gestational diabetes.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Gestational diabetes * Signed "Informed consent" * Will be expected to participate in ordinary child health care. * Access to Internet via computer, pad or phone Exclusion Criteria: * Manifest diabetes mellitus before pregnancy. * Other conditions, e.g. endocrine disorders, or treatment, e.g. cortisone medication, that could affect blood glucose control * Suspicion of type 1 diabetes mellitus as assessed by GAD antibodies or clinical history * Participation in other concomitant research study that could interfere with the study parameters * Other disease, treatment or condition that according to the Principal Investigator precludes participation

Primary outcome measure(s)

  • Diabetes mellitus type 2 — Four years post partum
    Number of women developing typ 2 diabetes

Trial sites (1)

FacilityCityRegionStatus
Maternity Ward, Västra Götaland Skövde Sweden Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05112588 on ClinicalTrials.gov ↗ ← All trials in Sweden